TYRP1 mRNA goes fishing for miRNAs in melanoma
Nature Cell Biology 19, 1311 (2017). doi:10.1038/ncb3637 Authors: Maria S. Soengas &Eva Hernando A variety of non-coding RNAs have been reported as endogenous sponges for cancer-modulating miRNAs. However, miRNA trapping by transcripts with protein-coding functions is less understood. The mRNA of TYRP1 is now found to sequester the tumour suppressor miR-16 on non-canonical miRNA response elements in melanoma, thereby promoting malignant growth.
AbstractAdoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] engineered T cells) to mediate cancer rejection. In recent years, some ACTs have produced unprecedented breakthrough responses: TIL therapy has moved from melanoma to solid tumor a pplications, TCR-engineered cells are developed for hematologic and solid tumors, and CAR-engineered T cells have ...
ConclusionAvelumab showed durable responses, promising survival outcomes, and an acceptable safety profile in patients with previously treated metastatic melanoma.Trial registrationClinicalTrials.gov identifier:NCT01772004.
In this study, we show that PANX1 is highly expressed in human melanoma tumors at all stages of disease progression, as well as in patient-derived cells and established melanoma cell lines. Reducing PANX1 protein levels using shRNA or inhibiting channel function with the channel blockers, carbenoxolone (CBX) and probenecid (PBN), significantly decreased cell growth and migration, and increased melanin production in A375-P and A375-MA2 cell lines. Further, treatment of A375-MA2 tumors in chicken embryo xenografts with CBX or PBN significantly reduced melanoma tumor weight and invasiveness. Blocking PANX1 channels with PBN r...
ConclusionsPKP1 was identified as a new potential tumor suppressor in human melanoma, likely through regulating calcium signaling pathways.Graphical abstract
Publication date: 14 January 2019Source: Cancer Cell, Volume 35, Issue 1Author(s): Angelica Ortiz, Jun Gui, Farima Zahedi, Pengfei Yu, Christina Cho, Sabyasachi Bhattacharya, Christopher J. Carbone, Qiujing Yu, Kanstantsin V. Katlinski, Yuliya V. Katlinskaya, Simran Handa, Victor Haas, Susan W. Volk, Angela K. Brice, Kim Wals, Nicholas J. Matheson, Robin Antrobus, Sonja Ludwig, Theresa L. Whiteside, Cindy SanderSummaryTumor-derived extracellular vesicles (TEV) “educate” healthy cells to promote metastases. We found that melanoma TEV downregulated type I interferon (IFN) receptor and expression of IFN-inducible ...
A new study from the University of Utah Health has found that the states with the lowest incidence of melanoma, including Texas, Louisiana and Alabama, have the worst survival rates.
Conditions: Breast Carcinoma; Colorectal Carcinoma; Community Practice; Lung Carcinoma; Melanoma; Solid Neoplasm Intervention: Other: Survey Administration Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI) Not yet recruiting
(University of Utah Health) Researchers at University of Utah Health conducted a state-by-state analysis to understand the geographic disparities for patients diagnosed with melanoma. The results of their study suggest that lower survival is associated with more practicing physicians in a region and higher population of Caucasians.
Researchers studied whether the mechanistic target of mTORC2 directs UVB –induced apoptosis by regulating the expression of NOXA downstream of FOXO3a.
Conclusions Cancer survivors have increased risk and excess incidence of primary pancreatic NET compared with the population, particularly for certain primary sites. High-risk patients should receive regular follow-up screenings, counseling to reduce carcinogen exposure, and lifestyle interventions.